A woman with ovarian cancer wearing a coat and green jumper walking down a hospital corridor

ARIEL 4: A study of rucaparib or chemotherapy in BRCA positive ovarian cancer

Trial at a glance

Open trial

  • Cancer type: Epithelial – high-grade serous and endometrioid | Prevention/BRCA
  • Treatment stage: Recurrence
  • Acronym: Ariel 4

ARIEL4: A study of rucaparib versus chemotherapy in BRCA-positive ovarian, fallopian tube or primary peritoneal cancer

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be able to take part in this clinical trial if you:

  • relapsed, high-grade ovarian, fallopian tube or primary peritoneal cancer
  • had two previous courses of chemotherapy
  • a BRCA1 or BRCA2 gene mutation
  • not had treatment with PARP inhibitors or single-agent paclitaxel before
  • not needed treatment with chemotherapy in the past six months

This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.

About the trial

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments.

The drugs involved in this trial:

  • Rucaparib – a targeted treatment known as a PARP inhibitor
  • Paclitaxel – a standard chemotherapy drug
  • Carboplatin or cisplatin – standard chemotherapy drugs

If you take part in this study, you'll be randomised (placed into a treatment group by a computer) into one of three treatment groups:

  • Rucaparib – tablets to be taken by mouth twice a day.
  • Single-agent paclitaxel – given through the vein (intravenously). 
  • Single-agent platinum or two chemotherapy drugs – this decision will be made by the oncologist caring for you.

If a woman's cancer progresses on the trial and she is receiving one of the chemotherapy drugs there is the option for her to move over onto the rucarparib treatment arm instead.